MegaTALs

A rare-cleaving nuclease architecture for therapeutic genome engineering

Sandrine Boissel, Jordan Jarjour, Alexander Astrakhan, Andrew Adey, Agnès Gouble, Philippe Duchateau, Jay Shendure, Barry L. Stoddard, Michael T. Certo, David Baker, Andrew M. Scharenberg

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Rare-cleaving endonucleases have emerged as important tools for making targeted genome modifications. While multiple platforms are now available to generate reagents for research applications, each existing platform has significant limitations in one or more of three key properties necessary for therapeutic application: efficiency of cleavage at the desired target site, specificity of cleavage (i.e. rate of cleavage at 'off-target' sites), and efficient/facile means for delivery to desired target cells. Here, we describe the development of a single-chain rare-cleaving nuclease architecture, which we designate 'megaTAL', in which the DNA binding region of a transcription activator-like (TAL) effector is used to 'address' a site-specific meganuclease adjacent to a single desired genomic target site. This architecture allows the generation of extremely active and hyper-specific compact nucleases that are compatible with all current viral and nonviral cell delivery methods.

Original languageEnglish (US)
Pages (from-to)2591-2601
Number of pages11
JournalNucleic Acids Research
Volume42
Issue number4
DOIs
StatePublished - Feb 2014
Externally publishedYes

Fingerprint

Genome
Endonucleases
DNA
Therapeutics
Research
Transcription Activator-Like Effectors

ASJC Scopus subject areas

  • Genetics

Cite this

Boissel, S., Jarjour, J., Astrakhan, A., Adey, A., Gouble, A., Duchateau, P., ... Scharenberg, A. M. (2014). MegaTALs: A rare-cleaving nuclease architecture for therapeutic genome engineering. Nucleic Acids Research, 42(4), 2591-2601. https://doi.org/10.1093/nar/gkt1224

MegaTALs : A rare-cleaving nuclease architecture for therapeutic genome engineering. / Boissel, Sandrine; Jarjour, Jordan; Astrakhan, Alexander; Adey, Andrew; Gouble, Agnès; Duchateau, Philippe; Shendure, Jay; Stoddard, Barry L.; Certo, Michael T.; Baker, David; Scharenberg, Andrew M.

In: Nucleic Acids Research, Vol. 42, No. 4, 02.2014, p. 2591-2601.

Research output: Contribution to journalArticle

Boissel, S, Jarjour, J, Astrakhan, A, Adey, A, Gouble, A, Duchateau, P, Shendure, J, Stoddard, BL, Certo, MT, Baker, D & Scharenberg, AM 2014, 'MegaTALs: A rare-cleaving nuclease architecture for therapeutic genome engineering', Nucleic Acids Research, vol. 42, no. 4, pp. 2591-2601. https://doi.org/10.1093/nar/gkt1224
Boissel, Sandrine ; Jarjour, Jordan ; Astrakhan, Alexander ; Adey, Andrew ; Gouble, Agnès ; Duchateau, Philippe ; Shendure, Jay ; Stoddard, Barry L. ; Certo, Michael T. ; Baker, David ; Scharenberg, Andrew M. / MegaTALs : A rare-cleaving nuclease architecture for therapeutic genome engineering. In: Nucleic Acids Research. 2014 ; Vol. 42, No. 4. pp. 2591-2601.
@article{1064d5900c274b8fa72d9f2a7386dbe9,
title = "MegaTALs: A rare-cleaving nuclease architecture for therapeutic genome engineering",
abstract = "Rare-cleaving endonucleases have emerged as important tools for making targeted genome modifications. While multiple platforms are now available to generate reagents for research applications, each existing platform has significant limitations in one or more of three key properties necessary for therapeutic application: efficiency of cleavage at the desired target site, specificity of cleavage (i.e. rate of cleavage at 'off-target' sites), and efficient/facile means for delivery to desired target cells. Here, we describe the development of a single-chain rare-cleaving nuclease architecture, which we designate 'megaTAL', in which the DNA binding region of a transcription activator-like (TAL) effector is used to 'address' a site-specific meganuclease adjacent to a single desired genomic target site. This architecture allows the generation of extremely active and hyper-specific compact nucleases that are compatible with all current viral and nonviral cell delivery methods.",
author = "Sandrine Boissel and Jordan Jarjour and Alexander Astrakhan and Andrew Adey and Agn{\`e}s Gouble and Philippe Duchateau and Jay Shendure and Stoddard, {Barry L.} and Certo, {Michael T.} and David Baker and Scharenberg, {Andrew M.}",
year = "2014",
month = "2",
doi = "10.1093/nar/gkt1224",
language = "English (US)",
volume = "42",
pages = "2591--2601",
journal = "Nucleic Acids Research",
issn = "0305-1048",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - MegaTALs

T2 - A rare-cleaving nuclease architecture for therapeutic genome engineering

AU - Boissel, Sandrine

AU - Jarjour, Jordan

AU - Astrakhan, Alexander

AU - Adey, Andrew

AU - Gouble, Agnès

AU - Duchateau, Philippe

AU - Shendure, Jay

AU - Stoddard, Barry L.

AU - Certo, Michael T.

AU - Baker, David

AU - Scharenberg, Andrew M.

PY - 2014/2

Y1 - 2014/2

N2 - Rare-cleaving endonucleases have emerged as important tools for making targeted genome modifications. While multiple platforms are now available to generate reagents for research applications, each existing platform has significant limitations in one or more of three key properties necessary for therapeutic application: efficiency of cleavage at the desired target site, specificity of cleavage (i.e. rate of cleavage at 'off-target' sites), and efficient/facile means for delivery to desired target cells. Here, we describe the development of a single-chain rare-cleaving nuclease architecture, which we designate 'megaTAL', in which the DNA binding region of a transcription activator-like (TAL) effector is used to 'address' a site-specific meganuclease adjacent to a single desired genomic target site. This architecture allows the generation of extremely active and hyper-specific compact nucleases that are compatible with all current viral and nonviral cell delivery methods.

AB - Rare-cleaving endonucleases have emerged as important tools for making targeted genome modifications. While multiple platforms are now available to generate reagents for research applications, each existing platform has significant limitations in one or more of three key properties necessary for therapeutic application: efficiency of cleavage at the desired target site, specificity of cleavage (i.e. rate of cleavage at 'off-target' sites), and efficient/facile means for delivery to desired target cells. Here, we describe the development of a single-chain rare-cleaving nuclease architecture, which we designate 'megaTAL', in which the DNA binding region of a transcription activator-like (TAL) effector is used to 'address' a site-specific meganuclease adjacent to a single desired genomic target site. This architecture allows the generation of extremely active and hyper-specific compact nucleases that are compatible with all current viral and nonviral cell delivery methods.

UR - http://www.scopus.com/inward/record.url?scp=84895783187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895783187&partnerID=8YFLogxK

U2 - 10.1093/nar/gkt1224

DO - 10.1093/nar/gkt1224

M3 - Article

VL - 42

SP - 2591

EP - 2601

JO - Nucleic Acids Research

JF - Nucleic Acids Research

SN - 0305-1048

IS - 4

ER -